Mechanisms of Resistance to Anti-CD38 Daratumumab in Multiple Myeloma

Daratumumab (Dara) is the first-in-class human-specific anti-CD38 mAb approved for the treatment of multiple myeloma (MM). Although recent data have demonstrated very promising results in clinical practice and trials, some patients do not achieve a partial response, and ultimately all patients under...

Descripción completa

Detalles Bibliográficos
Autores principales: Saltarella, Ilaria, Desantis, Vanessa, Melaccio, Assunta, Solimando, Antonio Giovanni, Lamanuzzi, Aurelia, Ria, Roberto, Storlazzi, Clelia Tiziana, Mariggiò, Maria Addolorata, Vacca, Angelo, Frassanito, Maria Antonia
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2020
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7017193/
https://www.ncbi.nlm.nih.gov/pubmed/31936617
http://dx.doi.org/10.3390/cells9010167
_version_ 1783497146388971520
author Saltarella, Ilaria
Desantis, Vanessa
Melaccio, Assunta
Solimando, Antonio Giovanni
Lamanuzzi, Aurelia
Ria, Roberto
Storlazzi, Clelia Tiziana
Mariggiò, Maria Addolorata
Vacca, Angelo
Frassanito, Maria Antonia
author_facet Saltarella, Ilaria
Desantis, Vanessa
Melaccio, Assunta
Solimando, Antonio Giovanni
Lamanuzzi, Aurelia
Ria, Roberto
Storlazzi, Clelia Tiziana
Mariggiò, Maria Addolorata
Vacca, Angelo
Frassanito, Maria Antonia
author_sort Saltarella, Ilaria
collection PubMed
description Daratumumab (Dara) is the first-in-class human-specific anti-CD38 mAb approved for the treatment of multiple myeloma (MM). Although recent data have demonstrated very promising results in clinical practice and trials, some patients do not achieve a partial response, and ultimately all patients undergo progression. Dara exerts anti-MM activity via antibody-dependent cell-mediated cytotoxicity (ADCC), antibody-dependent cellular phagocytosis (ADCP), complement-dependent cytotoxicity (CDC), and immunomodulatory effects. Deregulation of these pleiotropic mechanisms may cause development of Dara resistance. Knowledge of this resistance may improve the therapeutic management of MM patients.
format Online
Article
Text
id pubmed-7017193
institution National Center for Biotechnology Information
language English
publishDate 2020
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-70171932020-02-28 Mechanisms of Resistance to Anti-CD38 Daratumumab in Multiple Myeloma Saltarella, Ilaria Desantis, Vanessa Melaccio, Assunta Solimando, Antonio Giovanni Lamanuzzi, Aurelia Ria, Roberto Storlazzi, Clelia Tiziana Mariggiò, Maria Addolorata Vacca, Angelo Frassanito, Maria Antonia Cells Review Daratumumab (Dara) is the first-in-class human-specific anti-CD38 mAb approved for the treatment of multiple myeloma (MM). Although recent data have demonstrated very promising results in clinical practice and trials, some patients do not achieve a partial response, and ultimately all patients undergo progression. Dara exerts anti-MM activity via antibody-dependent cell-mediated cytotoxicity (ADCC), antibody-dependent cellular phagocytosis (ADCP), complement-dependent cytotoxicity (CDC), and immunomodulatory effects. Deregulation of these pleiotropic mechanisms may cause development of Dara resistance. Knowledge of this resistance may improve the therapeutic management of MM patients. MDPI 2020-01-09 /pmc/articles/PMC7017193/ /pubmed/31936617 http://dx.doi.org/10.3390/cells9010167 Text en © 2020 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (http://creativecommons.org/licenses/by/4.0/).
spellingShingle Review
Saltarella, Ilaria
Desantis, Vanessa
Melaccio, Assunta
Solimando, Antonio Giovanni
Lamanuzzi, Aurelia
Ria, Roberto
Storlazzi, Clelia Tiziana
Mariggiò, Maria Addolorata
Vacca, Angelo
Frassanito, Maria Antonia
Mechanisms of Resistance to Anti-CD38 Daratumumab in Multiple Myeloma
title Mechanisms of Resistance to Anti-CD38 Daratumumab in Multiple Myeloma
title_full Mechanisms of Resistance to Anti-CD38 Daratumumab in Multiple Myeloma
title_fullStr Mechanisms of Resistance to Anti-CD38 Daratumumab in Multiple Myeloma
title_full_unstemmed Mechanisms of Resistance to Anti-CD38 Daratumumab in Multiple Myeloma
title_short Mechanisms of Resistance to Anti-CD38 Daratumumab in Multiple Myeloma
title_sort mechanisms of resistance to anti-cd38 daratumumab in multiple myeloma
topic Review
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7017193/
https://www.ncbi.nlm.nih.gov/pubmed/31936617
http://dx.doi.org/10.3390/cells9010167
work_keys_str_mv AT saltarellailaria mechanismsofresistancetoanticd38daratumumabinmultiplemyeloma
AT desantisvanessa mechanismsofresistancetoanticd38daratumumabinmultiplemyeloma
AT melaccioassunta mechanismsofresistancetoanticd38daratumumabinmultiplemyeloma
AT solimandoantoniogiovanni mechanismsofresistancetoanticd38daratumumabinmultiplemyeloma
AT lamanuzziaurelia mechanismsofresistancetoanticd38daratumumabinmultiplemyeloma
AT riaroberto mechanismsofresistancetoanticd38daratumumabinmultiplemyeloma
AT storlazzicleliatiziana mechanismsofresistancetoanticd38daratumumabinmultiplemyeloma
AT mariggiomariaaddolorata mechanismsofresistancetoanticd38daratumumabinmultiplemyeloma
AT vaccaangelo mechanismsofresistancetoanticd38daratumumabinmultiplemyeloma
AT frassanitomariaantonia mechanismsofresistancetoanticd38daratumumabinmultiplemyeloma

Ejemplares similares